NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Active Not RecruitingNA

Sponsor: Wake Forest University Health Sciences

Conditions: Cancer, Gastrointestinal Cancer

Interventions: Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"

Countries: United States

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years at the time of consent.
* Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available.
* Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.

Exclusion Criteria:

• History of prior allogeneic hematopoietic cell transplantation or liver transplantation

Locations (1)

Charlotte, North Carolina, United States